Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
14 hedge funds and large institutions have $3.13M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding
Funds holding: 14 → 14 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
86% less capital invested
Capital invested by funds: $21.6M → $3.13M (-$18.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$124K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$89K |
| 3 |
Renaissance Technologies
New York
|
+$76.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.9K |
| 5 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
+$16.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$1.67M |
| 2 |
Morgan Stanley
New York
|
-$99.2K |
| 3 |
Citigroup
New York
|
-$27K |
| 4 |
JP Morgan Chase
New York
|
-$6K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$820 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.78M | +$89K | +217 | +5% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $575K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $341K | +$76.7K | +187 | +30% |
|
|
4
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $169K | +$124K | +303 | +300% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $111K | +$5.33K | +13 | +5% |
|
|
WAM
6
Warberg Asset Management
Winnetka,
Illinois
| $33K | +$2.87K | +7 | +10% |
|
|
7
Morgan Stanley
New York
| $30K | -$99.2K | -242 | -77% |
|
|
8
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $28K | -$820 | -2 | -3% |
|
9
Northern Trust
Chicago,
Illinois
| $26K | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| $19K | +$18.9K | +46 | New |
|
|
QPW
11
Quantum Private Wealth
Tampa,
Florida
| $16K | +$16.4K | +40 | New |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $4K | +$4.1K | +10 | New |
|
13
BlackRock
New York
| $1K | – | – | – |
|
|
KC
14
Kepos Capital
New York
| – | -$1.67M | -3,000 | Closed |
|
|
15
Citigroup
New York
| – | -$27K | -49 | Closed |
|
|
16
JP Morgan Chase
New York
| – | -$6K | -11 | Closed |
|
VRPX Hedge Fund Activity: Q2 2022 in Review
14 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q2 2022, worth a combined $3.13M — down 86% from $21.6M a quarter earlier.
Fund positioning in VRPX was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was PNC Financial Services Group, adding an estimated $124K. The largest seller was Kepos Capital, exiting entirely with an estimated $1.67M sold.
- 14 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $3.13M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 86% quarter-over-quarter.
- 3 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 3 closed out, a net change of 0 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was PNC Financial Services Group, an estimated $124K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Kepos Capital, an estimated $1.67M sold.
Based on aggregated 13F filings for Q2 2022.